7. Retrospective Evaluation (§§ 438.16(e) and 457.1201(e))
For states with a final ILOS cost percentage above 1.5 percent for any given year within the first five-year period for each ILOS is authorized and identified in the MCO, PIHP, or PAHP contract and subsequent to applicability date of this final rule (i.e. new ILOSs), a retrospective evaluation, of that five-year period, for that ILOS will be required for submission to CMS two years after completion of the five-year rating period.
Previously authorized ILOSs with a cost percentage above 1.5 percent in any of the first five rating periods subsequent to the applicability date of this final rule would also be required to have a retrospective evaluation submission due two years after either the five-year period that the ILOS was included in the MCO, PIHP, or PAHP contract or the rating-period year that the ILOS cost percentage exceeded 1.5 percent, whichever is later.
The first five-year rating period of the ILOSs’ contractual inclusion is the evaluation period. Additionally, CMS reserves the right to require retrospective ILOS evaluations for any ILOSs that exceed the 1.5 cost percentage subsequent to the distinct five-year rating periods identified for the new or previously authorized ILOSs, to ensure continuous monitoring of all ILOSs.
CMS encourages all states that include ILOSs in their managed care plan contracts to conduct a retrospective evaluation of all ILOSs. These evaluations should be completed for each managed care program, not across managed care programs or managed care plan contracts.
At a minimum, the evaluation must include cost, utilization, access, grievances and appeals, and quality of care for each ILOS. This must be completed separately for each managed care program that includes an ILOS States are required to evaluate the impact each ILOS had on utilization of State plan-covered services and settings, including any associated savings. The state would also be required to evaluate the trends in managed care plan and enrollee usage of ILOSs. In addition, CMS proposes to require that states use encounter data to evaluate if each ILOS is a cost effective and medically appropriate substitute for the identified State plan-covered service or setting, or that each ILOS is a cost effective measure to reduce or prevent the future need to use the identified State plan-covered service or setting. Other required evaluation components would include the impact of each ILOS on quality-of-care and health-equity efforts, appeals, grievances, and state fair-hearings reporting.
CMS encourages, but does not require that states procure an independent evaluator for ILOS evaluations. CMS suggests that states can leverage existing EQR activities and a new optional external quality review protocol to help evaluate the ILOSs. Because Myers and Stauffer qualifies as an EQRO, we can assist with this independent evaluation.